US007179821B2

(12) **United States Patent**
Smith et al.

(10) **Patent No.: US 7,179,821 B2**
(45) **Date of Patent: Feb. 20, 2007**

(54) **METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS**

(75) Inventors: **Craig P Smith**, Hillsborough, NJ (US); **Michel P Rathbone**, Hamilton, CA (US); **Margaret Petty**, Bridgewater, NJ (US); **David Rampe**, Bernardsville, NJ (US)

(73) Assignee: **Aventis Pharmaceuticals Inc.**, Bridgewater, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/079,366**

(22) Filed: **Mar. 14, 2005**

(65) **Prior Publication Data**

US 2005/0234105 A1 Oct. 20, 2005

Related U.S. Application Data

(60) Continuation of application No. 10/770,656, filed on Feb. 3, 2004, now abandoned, which is a division of application No. 10/076,191, filed on Feb. 14, 2002, now Pat. No. 6,967,210.

(60) Provisional application No. 60/268,846, filed on Feb. 15, 2001.

(30) **Foreign Application Priority Data**

Aug. 9, 2001 (GB) 0119435.6

(51) **Int. Cl.**
A61K 31/44 (2006.01)

(52) **U.S. Cl.** **514/339**; 514/323; 514/336; 514/337; 514/903

(58) **Field of Classification Search** ..... None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,970,218	A	11/1990	Effland
5,519,131	A	5/1996	Effland

FOREIGN PATENT DOCUMENTS

DE	43 25 491	2/1995
EP	0287982	10/1988
EP	0731108	9/1996
WO	WO98/14066	5/1996
WO	WO01/04091	1/2001

OTHER PUBLICATIONS

C.T. Bever, Jr., The Current Status of Studies of Aminopyrides in Patients with Multiple Sclerosis, Annals of Neurology, Boston, MA, vol. 36, 1994, pp. S118-S121.

Eglen, et al, Muscarinio receptor ligands and their therapeutic potential, Current Opinion in Chemical Biology, vol. 3, No. 4, Aug. 1999, pp. 426-432.

L. Tang et al., 4-Aminopyridine Derivatives: A Family of Novel Modulators of Voltage-Dependent Sodium Channels, Drug Development Research, vol. 44, No. 1, May 1998, pp. 8-13.

L. Tang et al., Effects of besipirdine at the voltage-dependant sodium channel, British Journal of Pharmacology, vol. 116, No. 5, 1995, pp. 2468-2472.

M Abou-Gharbia et al., IV Congress of the ECNP, Aggression and anxiety are the first components to respond to antidepressant therapy, Drug News and Perspectives, vol. 4, No. 10, Dec. 1, 1991, pp. 647-650.

P. Vlloslada et al., Human Nerve Growth Factor Protects Common Marmosets against AutoImmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System, Journ. of Experimental Medicine, vol. 191, No. 10, May 15, 2000, pp. 1799-1806.

R.M. Eglen et al., Muscarinc receptor ligands and their therapeutio potential, Current Opinion in Chemical Biology, vol. 3, No. 4, Aug. 1999, pp. 426-432.

Stedman's, No title—Stedman's Medical Dictionary, Stedman's Medical Dictionary, 25th Edition, Illustrated, 1994, pp. 391.

Tang, et al, Effects of bisipirdine at the voltage-dependent sodium channel, British Journal of Pharmacology, vol. 116, 1995, pp. 2468-2472.

W.J. Mysiw et al., Medications To Enhance Cognitive Functioning, Physical Medicine and Rehabilitation Clinics of North America, 1997, pp. 781-800.

Primary Examiner—Dwayne Jones
(74) *Attorney, Agent, or Firm*—Barbara E. Kurys

(57) **ABSTRACT**

N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.

2 Claims, 11 Drawing Sheets